康緣藥業(600557.SH):散寒化濕顆粒、熱毒寧注射液等品種被列入《新型冠狀病毒肺炎診療方案(試行第十版)》
格隆匯1月9日丨康緣藥業(600557.SH)公佈,近日,國家衞生健康委員會辦公廳和國家中醫藥管理局綜合司聯合發佈《新型冠狀病毒肺炎診療方案(試行第十版)》,公司獨家品種散寒化濕顆粒被該方案列為輕型和中型患者推薦用藥;獨家品種熱毒寧注射液被該方案列為重型和危重型患者推薦用藥;藿香正氣多劑型品種被該方案列為輕型患者以及兒童輕型和中型患者推薦用藥。
公司預計此次《新型冠狀病毒肺炎診療方案(試行第十版)》的發佈將對散寒化濕顆粒、熱毒寧注射液等品種的市場推廣和銷售將產生積極影響,但上述產品的銷售情況受疫情等因素影響存在較大不確定性,對公司近期經營業績的影響暫無法估計。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.